Michael Cowley and Ole Schmiedel lead an interactive session to help you decide when and how to use Contrave™ in your patients looking for sustainable weight management.
In many obese individuals, lifestyle interventions alone do not result in sustained bodyweight reductions, and pharmacotherapy is necessary. Medical weight management is recommended because even modest weight reductions of 5–10% can lead to significant improvements in weight-related morbidity and mortality.
In NZ, we have four medications registered for weight management, i.e., Orlistat, Phentermine, Liraglutide (Saxenda), and now the combination of Naltrexone/ Bupropion (Contrave™), which induces satiety and reduces cravings. Each has a specific mechanism of action, side-effect profile, and potential benefits.
00:00 Intro
01:16 Michael Cowley presentation
16:30 Ole Schmiedel presentation
46:31 Audience Q&A
0 Comments